- Home
- AMRN vs CHRS Comparison
AMRN vs CHRS Comparison
Compare AMRN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- CHRS
- Stock Information
- Founded
- AMRN 1989
- CHRS 2010
- Country
- AMRN Ireland
- CHRS United States
- Employees
- AMRN N/A
- CHRS N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- CHRS Health Care
- Exchange
- AMRN Nasdaq
- CHRS Nasdaq
- Market Cap
- AMRN 216.0M
- CHRS 84.2M
- IPO Year
- AMRN 1993
- CHRS 2014
- Fundamental
- Price
- AMRN $16.51
- CHRS $0.73
- Analyst Decision
- AMRN Strong Sell
- CHRS Buy
- Analyst Count
- AMRN 1
- CHRS 3
- Target Price
- AMRN $12.00
- CHRS $4.68
- AVG Volume (30 Days)
- AMRN 180.2K
- CHRS 1.3M
- Earning Date
- AMRN 07-30-2025
- CHRS 08-07-2025
- Dividend Yield
- AMRN N/A
- CHRS N/A
- EPS Growth
- AMRN N/A
- CHRS N/A
- EPS
- AMRN N/A
- CHRS N/A
- Revenue
- AMRN $214,112,000.00
- CHRS $272,251,000.00
- Revenue This Year
- AMRN N/A
- CHRS N/A
- Revenue Next Year
- AMRN $7.88
- CHRS $106.56
- P/E Ratio
- AMRN N/A
- CHRS N/A
- Revenue Growth
- AMRN N/A
- CHRS 19.87
- 52 Week Low
- AMRN $7.08
- CHRS $0.66
- 52 Week High
- AMRN $17.18
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- AMRN 71.62
- CHRS 41.45
- Support Level
- AMRN $12.30
- CHRS $0.72
- Resistance Level
- AMRN $17.18
- CHRS $0.77
- Average True Range (ATR)
- AMRN 1.09
- CHRS 0.04
- MACD
- AMRN 0.26
- CHRS 0.00
- Stochastic Oscillator
- AMRN 73.61
- CHRS 13.65
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.